Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 56

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 56
---
 presented exclude the Australian R&D tax incentive credit of approximately
$218,000.

    Schedule of significant expense categories 

    Category 
    Three Months Ended  
    Six Months Ended 

    September 30, 2025  
    September 30, 2024  
    September 30, 2025  
    September 30, 2024 
  
    Research and development¹ 
    $512,000  
    $262,000  
    $1,036,000  
    $702,000 
  
    General and administrative² 
    $739,000  
    $958,000  
    $1,475,000  
    $1,709,000 
  
    Cash used in operating activities³ 
    $1,657,000  
    $2,214,000  
    $3,372,000  
    $3,962,000 

Amounts in this table are rounded to the nearest
thousand.

    ¹
    Research and development expenses primarily include costs related to laboratory operations, clinical trial execution, investigational device testing, design iterations, and personnel expenses associated with research activities. These costs are recorded within payroll, professional fees, and general and administrative (“G&A”) expense on the face of the statements of operations, as the Company does not maintain a separate R&D line item. 

    ²
    General and administrative expenses encompass overhead, administrative costs associated with clinical trial operations, and certain manufacturing-related costs. R&D costs are included within these categories for financial reporting purposes and are not separately reclassified.

    ³
    Cash used in operating activities is the key internal performance metric tracked by the CODM to evaluate development progress, cash needs, and investment strategy in the absence of commercial revenue.

The Company does not allocate assets to operating
segments, nor does the CODM evaluate performance using a segment profit or loss measure. There were no changes in the internal reports
provided to or reviewed by the CODM during the periods presented.

Entity-Wide Information

    ·
    The Company did not recognize revenue during the six months ended September 30, 2025.

    ·
    All long-lived assets are located in the United States.

    ·
    A significant portion of clinical trial activity is conducted through the Company’s wholly owned subsidiary in Australia.

13. SUBSEQUENT EVENTS

On October 16, 2025, the Company implemented a
1-for